

SCIENCE VOLUNTEER

WARNING SIGNS

DONATE



Circulation

This site uses cookies. By continuing to browse this site you are agreeing to our use of cookies.

[Click here for more information.](#)



 FREE ACCESS | **ABSTRACT**

ARTERIOSCLEROSIS, THROMBOSIS, VASCULAR BIOLOGY

SESSION TITLE: DAMPS, INFECTION AND CARDIOVASCULAR METABOLISM

Abstract 10712: Observational Findings of PULS Cardiac Test Findings for Inflammatory Markers in Patients Receiving mRNA Vaccines

Steven R Gundry

Originally published 8 Nov 2021 | Circulation. 2021;144:A10712

This article has an expression of concern 

Expression of Concern: Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning

is corrected by 

Correction to: Abstract 10712: Mrna COVID Vaccines Dramatically Increase Endothelial Inflammatory Markers and ACS Risk as Measured by the PULS Cardiac Test: a Warning

Abstract

This clinic has been using the PULS Cardiac Test (Predictive Health Diagnostics Co., Irvine, CA) a clinically utilized measurement of multiple protein biomarkers, which generates a score predicting the 5 yr risk (percentage chance) of a new Acute Coronary Syndrome (ACS) called the PULS Score. The score is based on changes from the norm of multiple protein inflammatory biomarkers including IL-16, a proinflammatory cytokine, soluble Fas, an inducer of apoptosis, and Hepatocyte Growth Factor (HGF) which serves as a marker for chemotaxis of T-cells into epithelium and cardiac tissue, among other markers. Elevation above the norm increases the PULS score, while decreases below the norm lowers the PULS score. The PULS score has been measured every 3-6 months in our

patient population for 8 years. Recently, with the advent of the mRNA COVID 19 vaccines (vac) by Moderna and Pfizer, we tracked the changes of the PULS score and three of the inflammatory markers it measures in all of our patients consecutively receiving these vaccines.

This report summarizes those results. A total of 566 pts, aged 28 to 97, M:F ratio 1:1 seen in a preventive cardiology practice had a previously scheduled PULS test drawn from 2 to 10 weeks following the 2nd mRNA COVID shot and was compared to the pt's PULS test drawn 3 to 5 months previously pre-shot. Each vac pt's PULS score and inflammatory marker changes were compared to their pre-vac PULS score, thus serving as their own control. There was no comparison made with unvaccinated patients or pts treated with other vaccines.

Baseline IL-16 increased from 35+/-20 above the norm to 82 +/- 75 above the norm post-vac; sFas increased from 22+/- 15 above the norm to 46+/-24 above the norm post vac; HGF increased from 42+/-12 above the norm to 86+/-31 above the norm post vac. These changes resulted in an increase of the pre vac PULS score of predicted 11% 5 yr ACS risk to a post vac PULS score of a predicted 25% 5 yr ACS risk, based on data which has not been validated in this population. No statistical comparison was done in this observational study.

In conclusion, the mRNA vacs numerically increase (but not statistically tested) the markers IL-16, Fas, and HGF, all markers previously described by others for denoting inflammation on the endothelium and T cell infiltration of cardiac muscle, in a consecutive series of a single clinic patient population receiving mRNA vaccines without a control group.

Footnotes

Author Disclosures: For author disclosure information, please visit the AHA Scientific Sessions 2021 [Online Program Planner](#) and search for the abstract title.



[^ Back to top](#)



Circulation



Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)

Circulation

Circ: Arrhythmia and Electrophysiology

Circ: Genomic and Precision Medicine

Circ: Cardiovascular Imaging

Circ: Cardiovascular Interventions

Circ: Cardiovascular Quality & Outcomes

Circ: Heart Failure

Circulation Research

Hypertension

Stroke

Stroke: Vascular and Interventional Neurology

Journal of the American Heart Association (JAHA)

Journal Information

About

Editorial Board

Reprints

Customer Service and Ordering Information

AHA Journals RSS Feeds

For International Users

Institutions/Librarians FAQ

For Subscribers

Subscriber Help

Wolters Kluwer Privacy Policy

Subjects

All Subjects

Arrhythmia and Electrophysiology

Basic, Translational, and Clinical Research

Critical Care and Resuscitation

Epidemiology, Lifestyle, and Prevention

Genetics

Heart Failure and Cardiac Disease

Hypertension

Imaging and Diagnostic Testing

Intervention, Surgery, Transplantation

Quality and Outcomes

Stroke

Vascular Disease

Features 

[Bridging Disciplines](#)

[Circulation at Major Meetings](#)

[Special Themed Issues](#)

[Global Impact of the 2017 ACC/AHA Hypertension Guidelines](#)

[Circulation Supplements](#)

[Cardiovascular Case Series](#)

[ECG Challenge](#)

[Hospitals of History](#)

[On My Mind](#)

[Podcast Archive](#)

[- Circulation on the Run](#)

[- Subscribe to Circulation on the Run](#)

[- #FITFAVES](#)

[Circulation Doodle](#)

Resources & Education 

[AHA Guidelines and Statements](#)

[Circulation CME](#)

[Information for Advertisers](#)

For Authors & Reviewers 

[Instructions for Authors](#)

[Submission Site](#)

[Author Reprints](#)



American Heart Association®

National Center
7272 Greenville Ave.
Dallas, TX 75231

Customer Service
1-800-AHA-USA-1
1-800-242-8721

[Local Info](#)
[Contact Us](#)

ABOUT US

- [About the AHA/ASA](#) >
- [2016-17 Annual Report](#) >
- [AHA Financial Information](#) >
- [Careers](#) >
- [SHOP](#) >
- [Latest Heart and Stroke News](#) >
- [AHA/ASA Media Newsroom](#) >
- [Global Programs](#) >

OUR SITES

- [American Heart Association](#) >
- [American Stroke Association](#) >
- [Professional Heart Daily](#) >

[More Sites](#) >

TAKE ACTION

[Advocate](#) >

[Donate](#) >

[Planned Giving](#) >

[Volunteer](#) >

ONLINE COMMUNITIES

[AFib Support](#) >

[Garden Community](#) >

[Patient Support Network](#) >

[Privacy Policy](#) | [Copyright](#) | [Ethics Policy](#) | [Conflict of Interest Policy](#) | [Linking Policy](#) | [Diversity](#) | [Careers](#) |

[Suppliers & Providers](#) | [Accessibility Statement](#) | [State Fundraising Notices](#)

© American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. The American Heart Association is qualified 501(c)(3) tax-exempt organization.

*Red Dress TM DHHS, Go Red TM; AHA; National Wear Red Day [®] is registered trademark.

